CAM-H2 – New Treatment Option In HER2- Positive Cancer

Time: 11:30 am
day: Day 2 Track A

Details:

  • Building on strengths of single domain antibody-based platform
  • Evolving landscape in HER2-positive cancer
  • Ongoing CAM-H2 Phase I/II clinical study

Speakers: